logo
Share SHARE
FONT-SIZE Plus   Neg

Peregrine Cites Clinical Data To Highlight Potential Of Bavituximab

Clinical-stage biopharmaceutical company Peregrine Pharmaceuticals Inc (PPHM) Wednesday highlighted positive data from two Phase I investigator-sponsored trials and one preclinical study while evaluating the potential of bavituximab when combined with standard approved therapies in breast, liver and prostate cancers.

The company stated that in a Phase I trial of bavituximab with paclitaxel in five evaluable patients with HER-2 negative metastatic breast cancer, two patients achieved a complete tumor response, one achieved a partial response, and two had progressive disease according to Response Evaluation Criteria In Solid Tumors measurement criteria.

Additionally, the company presented data from a Phase I/II trial investigating bavituximab with sorafenib in patients with advanced hepatocellular carcinoma, in which no dose-limiting toxicities or serious adverse events were observed in the first phase of the trial.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
TCL Communications CEO Nicolas Zibell announced the plan to launch new Blackberry brand smartphone with superior security features. The new android phone BlackBerry KeyOne will be a beginning of a new story, he noted. Though the iPhones with smarter and popular features killed the Canadian smartphone maker, the BlackBerry brand has been maintaining strong fan-following around the globe. Its secu In response to stiff competition from its rivals, AT&T Inc. has lowered the price of its unlimited data plan and is also offering a video credit if customers subscribe to a video service plan. The unlimited mobile data plan was made available to all AT&T customers less than two weeks ago. The plan for a single phone will now cost $90 for the first line, a price cut of $10. Discount-store operator Target, Inc. on Tuesday reported a 43 percent decline in profit in the fourth quarter from last year, reflecting lower sales and weaker margins. In addition, the prior-year period's results included a one-time gain. Adjusted earnings per share for the latest quarter missed analysts' expectations.
comments powered by Disqus
Follow RTT